Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | PGK1 | P00558 | 2/20 | 0.32 |
| ▸ | PGK2 | P07205 | 2/20 | 0.32 |
| ▸ | PPIP5K2 | O43314 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239052 | 0.81 | CYP4F2 (0.36) | ALDH1A1 | |
| SCHEMBL2721087 | 0.79 | PTPN1 (0.44) | PTPN1 | |
| SCHEMBL2234955 | 0.78 | LPAR1 (0.33) | ALDH1A1 | |
| SCHEMBL337595 | 0.77 | MMP1 (0.34) | PTPN1PPIP5K2ALDH1A1 | |
| SCHEMBL2238373 | 0.75 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL2154821 | 0.74 | PGK1 (0.33) | PTPN1PGK1PGK2 | |
| SCHEMBL2238607 | 0.73 | FDPS (0.45) | PTPN1 | |
| SCHEMBL2236082 | 0.73 | PTPN1 (0.33) | PTPN1PGK1PGK2CNR2 | |
| SCHEMBL1751362 | 0.73 | PTPN1 (0.33) | PTPN1CNR2 | |
| SCHEMBL2239046 | 0.73 | HTT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090297967-A1 | PHOSPHONATE HOLE BLOCKING LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-12-03 | — | — | US | claimed |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | claimed |
| EP-1865959-A2 | PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | claimed |
| WO-2006104917-A2 | PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| US-12159967-B2 | Nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-03 | — | — | US | disclosed |
| US-12009482-B2 | Nonaqueous electrolytic solution and electrical storage device including the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-06-11 | — | — | US | disclosed |
| EP-3943479-B1 | PROCESSES FOR PREPARING 5,5-DIMETHYL-2-OXO-3-CYCLOPENTENE-1-CARBOXYLATE COMPOUNDS AND 3,5,5-TRIMETHYL-2-OXO-3-CYCLOPENTENE-1-CARBOXYLATE COMPOUNDS FROM 3,3-DIMETHYL-1-BUTENE-1,4-DICARBOXYLATE COMPOUNDS AND 1,3,3-TRIMETHYL-1-BUTENE-1,4-DICARBOXYLATE COMPOUNDS, AND 1,3,3-TRIMETHYL-1-BUTENE-1,4-DICARBOXYLATE COMPOUNDS | SHINETSU CHEMICAL CO (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-20240128511-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-04-18 | — | — | US | disclosed |
| US-11942601-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4318719-A2 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4030524-B1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-4959360-A | α-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
| WO-1990002740-A1 | 2-OXA-BICYCLO[2.2.1]HEPTANE DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1990-03-22 | — | — | WO | disclosed |
| EP-0358290-A1 | 2-Oxa-bicyclo[2.2.1]heptane derivatives and medicines containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-03-14 | — | — | EP | disclosed |
| WO-1989012054-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989012050-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0344980-A2 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0344979-A2 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0342541-A2 | Retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | PTPN1 2282/4885PGK1 2389/4885PGK2 1156/4885 |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | CYP2S1, CYP2F1, CBR3 | PTPN1 2339/4885PGK1 2053/4885PGK2 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.